Literature DB >> 7714723

Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle.

S H Klang1, J Frucht-Pery, A Hoffman, S Benita.   

Abstract

Fine, homogeneous, positively-charged emulsions with a mean droplet size of 138 +/- 71 nm and a zeta potential value of 41.06 mV were prepared using a combination of emulsifiers comprising phospholipids, poloxamer 188, and stearylamine. The pH of these emulsions decreased with time. However, the extent of decrease was dependent on the storage temperature. The mean droplet size of the emulsions that had been prepared with 1% poloxamer began to increase slightly after six months' storage, particularly when stored at 23 and 37 degrees C. However, emulsions prepared with 2% poloxamer remained stable for at least 10 months at 4 degrees C, suggesting that the poloxamer 188 concentration is critical for prolonged emulsion stability. The results of the ocular tolerance study in rabbit eye indicate that hourly administration of a positively-charged emulsion vehicle was well tolerated without any toxic or inflammatory response to the ocular surface during the five days of the study. Scanning electron microscopy revealed a normal corneal surface, which was not different from that of the animals treated with physiological saline. No marked acute toxicity was observed when 0.6 mL of positively-charged emulsion was injected intravenously to BALB/c mice. Furthermore, no difference was noted between this group of animals and the group injected with the marketed Intralipid emulsion. These results were further confirmed in a rat study where there were no deaths following intravenous injection of 3.3 mL per rat of the positively-charged emulsion or Intralipid. Neither emulsion elicited any hepatotoxic or nephrotoxic effects. The overall results suggest that the novel positively-charged emulsion is suitable for parenteral use, and for ocular application.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7714723     DOI: 10.1111/j.2042-7158.1994.tb03254.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

Review 1.  Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.

Authors:  I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

2.  Submicron cationic emulsions as a new delivery system for oligonucleotides.

Authors:  H Teixeira; C Dubernet; F Puisieux; S Benita; P Couvreur
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

3.  A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies.

Authors:  Ting Zhang; Yong Zheng; Qiang Peng; Xi Cao; Tao Gong; Zhirong Zhang
Journal:  Int J Nanomedicine       Date:  2013-03-20

4.  Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.

Authors:  Frederic Lallemand; Philippe Daull; Simon Benita; Ronald Buggage; Jean-Sebastien Garrigue
Journal:  J Drug Deliv       Date:  2012-02-27

5.  Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide.

Authors:  John Youshia; Amany O Kamel; Abdelhameed El Shamy; Samar Mansour
Journal:  Int J Nanomedicine       Date:  2012-05-17

Review 6.  Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery.

Authors:  Philippe Daull; Frédéric Lallemand; Jean-Sébastien Garrigue
Journal:  J Pharm Pharmacol       Date:  2014-04       Impact factor: 3.765

Review 7.  Natural Ergot Alkaloids in Ocular Pharmacotherapy: Known Molecules for Novel Nanoparticle-Based Delivery Systems.

Authors:  Iara Baldim; Wanderley P Oliveira; Varsha Kadian; Rekha Rao; Nitesh Yadav; Sheefali Mahant; Massimo Lucarini; Alessandra Durazzo; Raquel Da Ana; Raffaele Capasso; Selma B Souto; Antonello Santini; Eliana B Souto
Journal:  Biomolecules       Date:  2020-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.